Live attenuated influenza vaccine in children and teens with asthma or recurrent wheezing does not increase risk of
postvaccination lower respiratory events (LREs), according to an analysis published in Vaccine.
Conversely, the 3 rVSV NiV vaccine groups had animals in which detectable circulating NiV F, G, or F and G IgG developed, and circulating neutralizing antibody titers developed in all 3 groups by 28 days
postvaccination. Each vaccine cohort had detectable [NiV.sub.B] RNA in nasal swab samples and only the F and F/G groups in oral swab samples, but none of the cohorts had any detectable circulating [NiV.sub.B] RNA throughout the course of the study.
In addition to providing timely HepB-BD and HepB3 vaccination for HBV-exposed infants, 10 (28%) countries/areas administered HBIG to newborns of HBsAg-positive mothers, and seven (19%) provided
postvaccination serologic testing to determine the infection status of exposed infants.
The
postvaccination antipertussis geometric mean concentrations were noninferior in the Tdap group, compared with the Td group, Dr.
Seroconversion was defined as at least a fourfold serum hemagglutination inhibition (HI) antibody increase from prevaccination level (day 0), and seroprotection was defined as percent with HI titers of 1:40 or greater at
postvaccination day 28.
The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and
postvaccination data interpretation.
Group III was vaccinated I/P with 5 X [10.sup.8] CFU of [RB.sub.51] strain and injected at 7-day
postvaccination with 12.5 mg/Kg levamisole.
Postvaccination serologic testing results for infants aged <24 months exposed to hepatitis B virus at birth: United States, 2008-2011.
"Compared with [patients] without DMARDs, patients [taking DMARDs] had lower
postvaccination antibody levels, [lower] mean fold increase in antibody concentration, and [a lower] percentage of patients reaching putative protective antibody levels for both serotypes," the authors wrote.
From a Phase 1A trial on NPC patients in Hong Kong and UK, the modified vaccinia Ankara- (MVA-) based LMP2 and EBNA1 (MVA-LMP2/EBNA1) vaccine has resulted in a
postvaccination immune boosting of CD8+ and CD4+ T-cell responses with low off-target toxicities in both Chinese and European descents [19, 20].